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Abstract 
 
Tuberculosis (TB) is known as one of the 10 causes of death by infectious agent, 
worldwide. It affects around 10.4 million people per year and is still associated with a 
high number of deaths. Although the incidence of TB has declined in recent years, with 
HIV coinfection and the increasing appearance of multiple antibiotic resistance (MDR-
TB) or cases of extensive resistance to antibiotics (XDR-TB), it’s necessary the 
development of new effective TB therapy. Cationic antimicrobial peptides (CAMPs) 
emerge in the research as safe and effective against a variable range of bacterial and 
fungi pathogens, including Mycobacterium tuberculosis (Mtb). In addition, cinnamic acid 
had shown an interesting antimicrobial activity, particularly against TB. In the present 
project we synthesized, purified and characterized 10 peptides CAMP, which five present 
an N-terminal modification with addition of a cinnamic acid derivate, and also studied the 
antimicrobial activity against clinical isolates of Mtb and MDR-TB. In order to determine 
the cytotoxicity of AMPs towards eukaryotic cells, we performed a MTS assay in TPH-1 
cells as the macrophage model. Almost all modified CAMP presented a enhance activity 
against both Mtb strains and were capable to disrupt heavily clumping of mycobacteria 
in culture. Moreover, all modified CAMPs were able to substantial inhibit the intra cellular 
growth of both strain at low concentrations. 
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Resumo 
 
A Tuberculose (TB) caracteriza-se por ser uma doença infeciosa grave que, a nível 
global, afeta por ano cerca de 10,4 milhões de pessoas, estando ainda associada a um 
grande número de mortes. Apesar de nos últimos anos a taxa de incidência de TB ter 
diminuído, com a coinfecção com HIV e o aparecimento crescente de casos com 
resistência múltipla a antibióticos (MDR-TB) ou casos de resistência extensa a 
antibióticos (XDR-TB), tornaram urgente o desenvolvimento de terapias efetivas contra 
a TB. Os péptidos catiónicos antimicrobianos (CAMPs) surgem na investigação como 
sendo seguros e eficazes contra diversos patogénicos, incluído Mycobacterium 
tuberculosis (Mtb). Para além disso, os ácidos cinâmicos têm demonstrado um potencial 
antimicrobiano, também contra a TB. No presente projeto, foram sintetizados, 
purificados e caracterizados 10 péptidos CAMPs, nos quais 5 apresentavam 
modificação N-terminal com adição de um derivado ácido cinâmico, e foi igualmente 
estudada a atividade antimicrobiana contra Mtb e MDR-TB. O grau de citotoxicidade 
provocado por estes 10 CAMPs foi calculado por MTS em células TPH-1 previamente 
diferenciadas em macrófagos. Quase todos os CAMPs modificados apresentaram um 
aumento da atividade contra Mtb e MDR. Todos os CAMPs modificados foram capazes, 
em cultura, de quebrar agregados de Mtb e inibir substancialmente, em concentrações 
baixas, o crescimento celular de ambas as estirpes estudadas. 
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PMA - phorbol-myristate actate 
PZA - Pyrazinamide 
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RR-MPLC - Reverse Phase Medium-Pressure Liquid Chromatography 
Rt - retention time 
SM - Sphingomyelin 
SPPS - Solid Phase Peptide Synthesis 
STR – streptomycin 
TB- Tuberculosis 
TBTU - N,N,N′,N′-Tetramethyl-O-(benzotriazol-1-yl)uronium tetrafluoroborate 
tBu - tert-butyl 
TFA - trifluoroacetic acid 
TIS – Triisopropylsilane 
WHO – World health organization 
XDR-TB – Extensive drug resistant tuberculosis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 									FCUP	
Development	of	new	antimicrobial	peptides	against	Mtb	
	
	
16	
Objectives 
 
The main goal of the work developed in this thesis was the synthetises of new cationic 
antimicrobial peptides using cinnamic acids. 
 
CAMP(n): 
1 – WKWLKKWIK 
2 – WRKFWKYLK 
3 – RLWWWWRRR 
4 – RIRRWKFRW 
5 – RQRRVVIWW 
 
Cin+CAMP(n): 
1 - trans cinnamic+WKWLKKWIK 
2 - p-methoxycinnamic+WRKFWKYLK 
3 - 3,4-Dimethoxycinnamic+RLWWWWRRR 
4 - o-Nitrocinnamic+RIRRWKFRW 
5 - trans cinnamic+RQRRVVIWW 
 
Furthermore, the work aimed the study of the respective antimicrobial activity against 
Mtb and MDR-TB, as well to evaluate the cytotoxicity against TPH-1 cells differentiated 
into macrophages. 
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1. Introduction 
 
Human Tuberculosis 
 
1.1. History 
 
In the study of tuberculosis, René Laennec a French physician holds an important 
position in medical history being one of the pioneers of clinical-pathological correlations 
and his descriptions of pulmonary lesions in patients. In this work, published in 1821 
entitled 'A treatise on diseases of the chest', Laennec demonstrated drawn images of 
tuberculosis cavities and detailed descriptions of the pathologic changes ceasing with 
now known necrosis of the tissues. Through the examination of a patient body, he 
observed pathological similar lesions diffuse in different organs due to the same 
causative illness. However, he didn’t find the cause behind the disease. Nevertheless, 
in 1868 a French military physician, Jean-Antoine Villemin, made a landmark study 
entitled ''Etudes sur la tuberculosis', on this research he described the transmissibility 
capability of tuberculosis infect throughout species such as from human to rabbits, from 
cows to rabbits and so on. Villemin exemplified the transmission of the disease to a rabbit 
with an injection of purulent liquid of tuberculosis cavities, yet he didn’t found the 
responsible agent.  The cause of tuberculosis was not found until Robert Koch 
contribution, being the first to identify and isolate the tubercle bacilli. Koch continued his 
work with the discovery of a substance, now known as tuberculin, and though that could 
have a potential impact on tuberculosis cure. Unfortunately for Koch, research tuberculin 
didn’t cure tuberculosis, even so, he was capable to report cell-mediated immune 
responses for the first time (Schluger 2005; Smith 2003). 
 
1.2. Mycobacterium tuberculosis 
 
Mycobacterium tuberculosis (Mtb) is an aerobic obligate pathogen with G+C rich content 
and rood shape morphology of 0.3-0.5 µM of diameter (Cole et al. 1998; Niederweiss 
2013). Even though Mtb is classified as gram-positive bacteria, the composition of the 
cell wall differs from other gram-positive bacteria (Figure 1). The composition of the 
mycobacterial cell wall is determined by the presence of peptidoglycan layer which is 
covalently attached to arabinogalactans linked to mycolic acids (Brown et al. 2015). 
Mycolic acids structure is defined by a long chain α-alkyl β-hydroxy fatty acids and 
corresponds to around 60% of the cell wall size. The biosynthesis of these structures 
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occurs with carboxylation of acetyl-CoA into acetyl-CoA carboxylase which is 
incorporated into the growing acyl chain during the repetitive cycle of fatty acid synthase 
(FAS) I and II reactions. FAS I catalyse the production of c24/C26-coA (alfa-branch) and 
FAS II elongates into meromycolic acid (C54/C56 – AcpM) (Pawelczyk and Kremer 
2014). The complexity lipid-rich cell wall provides protection to chemical injury, 
dehydration and contributes to the extended persistence of Mtb bacilli within the host 
cells. 
 
 
 
 
1.3. Transmission and Pathogenesis of Mtb 
 
Mtb is transmitted through the air in airborne droplet nucleic when patients with active 
disease cough, sneeze, speak or sing. Tuberculosis disease is characterised by four 
major stages. 
The first stage of infection occurs when the inhaled tuberculosis droplet reaches the 
alveolus, further implantation preferentially affect the middle and lower zones of the lungs 
(Leung 1999). Once lodged in the alveolus, Mtb bind to macrophage through mannose, 
complement and scavenger receptors and the bacilli are phagocytosis (van Crevel, et al. 
2002). Mtb is kept in macrophage phagosome and is able to block the normal fusion with 
lysosome which is responsible for the creation of a stress environment conditions (acid 
pH, ROS, enzymes and peptides). The protection capability of Mtb which inhibits 
phagosome-lysosome fusion has been associated with different mechanism of 
	
a)	Mycobacteria	 b)	Gram-positive	bacteria	
Figure	1-	Cell	wall	structure	of:	a)	Mycobacteria	consist	of	thin	layers	of	peptidoglycan	covalently	bond	
with	arabinogalactan,	and	a	thick	layer	of	mycolic	acids.	b)	Gram-positive	bacteria	have	a	single	lipid	
membrane	surrounded	by	a	thick	layer	of	peptidoglycan	and	lipoteichoic	acid.	(Adapted	from	Brown	et	al.	
2015) 
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response. One side is consider that affect Ca2+ response by preventing the increase of 
Ca2+ levels and is also postulated that mycobacterial phagosome is capable of recruit 
large amounts of Rab5 proteins which are associated with endosome trafficking of early 
endosome (Delogu et al. 2015; Smith 2003). Within 3 to 8 weeks the bacillus has multiply 
causing the host macrophage to burst forming the Ghon complex and free bacilli through 
lymphatic circulation are able to disseminate to more distant tissues and organs. 
The second stage, lasting about 3 months or delayed for up 2 years, is marked by the 
spread of Mtb throughout the body. When tuberculosis disease only affects the lungs is 
referred as pulmonary TB but can affect other organs such as larynx, the lymph nodes, 
pleural, the brain, the kidneys, or the bones and joints and is referred as extrapulmonary 
TB. In some infected individuals, an acute and fatal disease can occur in the form 
meningitis, if Mtb reach the nervous system. The case of miliary TB (when Mtb is 
disseminate through the all body) is normally associated with infants and children and 
severely immunocompromised individuals (Canadian Thoracic Society and The Public 
Health Agency of Canada and Licensor 2014). Clinical symptoms associated with TB 
reflect in systemic manifestations such as fever, anorexia, night sweats and cough from 
weeks to months. In approximately 5% of adult patients have a complete absence of 
symptoms (Leung 1999). 
On the last stage (resolution) the primary complex is associated with the stagnation of 
the disease up to 3 years and characterized by the continuous development of 
granulomatous focal lesions and extra pulmonary lesions. The diversity of clinical 
manifestations between TB patients is influenced by age and immune strength. The 
success of tuberculosis infection in the early stage is determined by the strength of the 
host immune response. Around 90-95% of cases of Mtb are restricted and arrest in its 
latent form where infected patients do not show any signs or symptoms. The ability of 
Mtb of resisting immune responses in periods of latent infection is an essential feature. 
Mtb is able to switch between dormant and active state replicating bacilli as constantly 
stimulates T-cell responses which prevent the emergence of TB disease (Delogu et al. 
2015). The maintenance of this persistent state is due to the incredible sensorial 
perception of the surrounding conditions and the composition of the extracellular matrix 
(Cole et al. 1998; Niederweiss 2013) (Figure 2). 
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1.4. Current treatment 
 
 
The standard treatment for new TB patient with the active TB disease, recommended by 
the World Health Organization (WHO 2016), is characterise by a 6 month regiment 
divided in intensive phase of isoniazida (INH), rifampin (RIF), pyrazinamide (PZA) and 
Etanbutol (EMB) for 2 months, followed by INH and RIF for further 4 months. The 
standard treatment rate of cure is 83%. In cases of latent Mtb infections treatment with 
antibiotic is indicated for prevention of the development of active TB. The treatment can 
be administrated with drug alone treatment of INH or RIF for 9 months or through drug 
combination by 2 months of RIF followed by 2 or 3 months of PZA (Table 1) (Gleeson 
and Decker 2006; Ormerod 2005). 
 
 
 
	
	
	
	
Figure	2	-	Chronological	events	after	inhalation	of	M.	tuberculosis.	Schematized	the	different	possible	scenarios	of	
Tuberculosis	disease.	(Adapted	from	van	Crevel	et	al.	2002)	
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INH introduced for the treatment of TB in 1952, was a high selectivity and antimicrobial 
activity against Mtb. The mechanism of action is composed by three steps: starting with 
activation of pro-drug into active drug, then INH binds to the target molecule and 
terminates with inhibition of mycolic acid synthesis. INH active form binds to the enoyl-
acyl carrier protein (ACP) reductase one of FAS II system enzyme and it also targets the 
enzyme Ketoacyl-ACP synthase A (KasA) responsible to elongate fatty acids chain 
(Figure 3). Unfortunately, INH is only active against growing Mtb and possess adverse 
drug reactions in some patients such as hepatotoxicity, rash, fever or arthralgia (Figure 
4). 
 
 
 
 
 
Table	1	-	Recommended	treatment	regimen	against	new	TB	cases.	
 Active Disease  
Treatment Time Drugs 
Intense phase 2 months INH+RIF+PZA+EMB 
Continuous Phase 4 months INH+RIF 
Latent Disease 
Treatment Time Drugs 
Drug Alone 9 months INH or RIF 
Drug Combination 2 months 
2-3 months 
RIF 
PZA 
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RIF applied on treatment regimens since 1968, not only target intracellular, semi dormant 
Mtb present in Necrotic granuloma lesions but also replicating Mtb. RIF are associated 
with inhibition of transcription. The drug binds to the b-subunit of the DNA-dependent 
RNA polymerase resulting on alteration of conformation which leads to protein 
mistranslation through the incorporation of mismatch codons. The side effects are 
associated with hepatotoxicity effects, gastrointestinal and hypersensitivity reactions 
(Kohanski et al. 2010) (Figure 4). 
EMB was first introduced in 1961 and is active against only to replicating Mtb. 
Responsible for inhibition of cell wall synthesis by targeting Arabinosyl transferase, EMB 
presents a bacteriostatic effect rather than bactericidal as the other compounds (Figure 
4). 
PZA, as excellent sterilizing effect on growing and not growing bacilli and is only active 
in acidic pH, reaching the Mtb in the interior of macrophages. (Somoskovi et al, 2001; 
Woods et al. 2012) (Figure 4). 
 
Figure	3	-	General	scheme	of	FAS-II	system	involved	in	mycolic	acids	biosynthesis.	Orange	frame	enzyme	targets	
of	INH.	(adapted	from	Yoya	2009). 
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1.5. Development of resistant strains 
 
Mtb is known as one of the most successful pathogens caused by an infectious 
organism. The discovery of streptomycin (STR) in 1945 for the treatment of TB made 
possible the cure of TB disease and boosted the development of new compounds. Over 
the years TB incidence decreased significantly, unfortunately the increasing epidemic 
acquire immune deficiency syndrome (AIDS) and the emergence of drug resistant 
consequently led to the recidivism of TB. Exposure to a drug induces stress responses 
that lead to both genetic and physiological mechanisms in order to survive (Reviewed in  
Chevalier et al. 2014 and Nguyen 2016).  
The drug resistant Mtb is acquired through spontaneous chromosomal mutations that 
gives advantage of the strain to resist an antibiotic. For each antibiotic resistance, Mtb 
can present mutation on gene or group genes which reflects with alteration on 
composition of the cell wall or with an effect on the antibiotic target (Hoagland et al. 
2016). The highly hydrophobic membrane cell wall of Mtb act as a selective barrier 
against antibiotic. Many mutated genes reported consequently changes in the 
membrane composition and fluidity (Cole et al. 1998). 
The effect on the antibiotic target mechanism consists in modifying the structure (e.g 
Mutations on rpoB are responsible for conformational change at beta-subunit of RNA 
polymerase leading to a decrease in binding affinity of Rif) suppression or 
overexpression (The suppression of the antibiotic target such as Catalase peroxidase 
which results in a decrease on prodrug activation of INH), inactive drugs through 
A B 
D C 
Figure	4	-	The	molecular	strutures	of	first	line	drugs	used	agaisnt	TB	(A	-	Rifampin;	B	-	Isoniazid;	C	-	
Pirazinamide;	D	–	Etambutol). 
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chemical modification (Mutations in pncA reducing conversion to active acid form of 
PZA), drug efflux (Tap, a transporter responsible for mycobacterial efflux of 
aminoglycosides, spectinomycin, tetracycline ) (Hoagland et al. 2016; Nguyen 2016; 
Sarathy et al. 2012). 
The Mtb resistant strain can be divided into three major group based on the level of 
antibiotic resistance: Multi-drug resistant tuberculosis (MDR-TB) with drug resistance to 
at least the first-line drugs INH and RIF, extensively drug-resistant tuberculosis (XDR-
TB) with drug resistance to the first line drugs INH and RIF and to specific second-line 
drug (resistant to quinolones and injectable drugs) and totally drug resistant tuberculosis 
(TDR-TB) drug resistance to all first and second line drugs. 
 
 
1.6. New drugs 
 
The development of new anti-tubercular drugs stagnated in time for over 50 years but 
with the synergy of TB with HIV, crescent multi drug resistances cases associated with 
exacerbate population growth culminated in an urgent need for new compounds. In the 
past few years, two new synthesis compounds have been approved for treatment of 
MDR-TB. 
Bedaquiline, the family of diarylquinolones are the most advance anti-tubercular drugs 
currently available in the market. This drug is active from both replicating and not 
replicating Mtb. The prime target of bedaquiline is F0 F1 ATP synthase main site of ATP 
production in non-replicating state. This mechanism of bedaquiline results in a new 
method to kill latent Mtb and MDR-TB strains. Bedaquiline shows a minimum inhibitory 
concentration (MIC) of 0.12 μg/mL for drug resistant isolates (Andries et al. 2005; 
Hoagland et al. 2016) (Figure 5). 
Delamanid is a nitro-dihydro-imidazooxazole derivative with a MIC of 0.012 μg/ml for 
drug resistant isolates. The mechanism of action is incompletely understood but involve 
inhibition of mycolic acid synthesis possibly via radical intermediate (Matsumoto et al. 
2006) (Figure 5). 
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1.7. The impact of Mtb in the world 
 
TB is considered one of the 10 top leading causes of disease and mortality due to an 
infection agent. In 2015, according to the World Health Organization (WHO 2016) report, 
there was 10.4 million new cases and 1.8 million of deaths caused by TB (1.4 million TB 
and 0.4 million resulting from coexistence with HIV), worldwide. 
Six countries accounted for 60% of new cases: India, Indonesia, China, Nigeria, Pakistan 
and South Africa (Figure 6). 
 
 
	
Figure	6	-	Estimated	TB	incidence	rates,	2015.	Adapted	from	(WHO	2016) 
 
A B 
Figure	5	-	Molecular	structures	of	(A)	Bedaquiline	and	(B)	Delamanid. 
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Although, in the last few years incidence rate as decreased to 22%, cases of MDR-TB 
are growing, striking almost 480.000 in 2015 (Figure 7). Main countries accounted for 
45% cases were India, China and the Russian Federation. The average proportion of 
MDR-TB cases with XDR-TB is 9.6%. 
 
	
Figure	7	-	Percentage	of	new	TB	cases	with	MDR-TB.	Adapted	from	(WHO	2016) 
 
 
 
Treatment of TB has become more difficult to achieve due in part to the duration of 
therapy and the crescent number of multiple drug resistance (MDR-TB and XDR-TB). 
Which leads to poor treatment outcomes and increased rate of mortality, reflecting in the 
urgent need to development new active drugs against drug resistance strains. 
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1.8. CAMPs 
 
The global health concern of emergence of TB resistance to current antibiotic has 
triggered the development of new more effective compounds. Cationic antimicrobial 
peptide (CAMP) based therapies are interesting candidates as alternative or adjuvant to 
antibiotic treatments. CAMP are considered ancient defensive weapons with a wide 
spectrum of activity against gram-positive and gram-negative bacteria, fungus, parasites 
and virus and extending used against cancer. Through interaction with the negatively 
charged membrane which creates a displacement of lipids, alteration of membrane 
structure and possibility internalization (Lakshmaiah et al. 2015). CAMPs often possess 
a selectivity towards microbial membranes due to this anionic composition which differs 
from eukaryotic cells. Eukaryotic membranes are usually composed by zwitterionic 
phospholipids such as phosphatidylcholine (PC) and phosphatidylethanolamine (PE), 
sphingomyelin (SM) and cholesterol (increase of membrane stability) creating a neutral 
charged membrane ( -15 mV electrochemical gradient). In contrast the composition of 
prokaryotic membranes its characterise by the present of net negative charge/highly 
electronegative composed by hydroxylated phospholipids phosphatidylglycerol (PG), 
cardiolipin and phosphatidylserine (130 to 150 mV electrochemical gradient) (Robert E 
W Hancock et al. 1998; Yeaman and Yount 2003). 
CAMPs are often small size (12-15 amino acid residue), cationic character (composed 
with positively charge Arginine and lysine residues) and amphipathic. (Robert E W 
Hancock et al.  1998)  There are four major groups based on CAMP structure: a-helical 
usually amphipatic in nature (e.g. LL37, cecropins or magainins); b-sheet characterised 
by the presence of two or more disulphide bonds (e.g. human defensins, plectasin or 
protegrins); extended associated with lack of secondary structure rich in proline, 
histidine, arginine or glycine residues (e.g. indolicidin); and b-hairpin are highly stable 
due to the presence of disulphide bonds between b-strands (e.g. Bactenecin) (Hancock 
and Sahl 2006). 
 
 
1.9. Natural occurring CAMPs 
 
CAMPS are usually found in bacteria, insects, plants and animals as host defence 
mechanism. In addition, CAMPs are considered multifunctional molecules with 
enormous proprieties such as anti-inflammatory, immunomodulatory, wound healing, 
cytokine release, chemoattraction and antimicrobial activity. 
	 									FCUP	
Development	of	new	antimicrobial	peptides	against	Mtb	
	
	
28	
Natural CAMPs in mammals are encoded through a specific gene, being constitutively 
expressed (basal levels) or rapidly transcribed triggered with exposition to pathogens 
(Jenssen et al. 2006; McPhee et al. 2005). 
Defensins and cathelicinds are the two major class of CAMPs present in the mammalian 
defence mechanism. 
Cathelicidin is expressed in macrophages, epithelial cells and mainly store within 
granules of neutrophil expressed in mucosal surfaces (mouth, lung, genitourinary tract 
and skin). Beyond antibacterial activity, cathelicidin exhibits chemotactic, endotoxin-
neutralizing, angiogenic, and wound healing proprieties (Jenssen et al. 2006). 
Defensins are class of cyclic peptides with antimicrobial activity and immunomodulatory 
responses as mediators between innate and adaptive immune system. Defensins are 
divided in 3 groups: a, b defensins and q-defensins (Jenssen et al. 2006). Four a human 
neutrophile defensins (HNP 1-4) are present in neutrophils being constitutive produce 
and HNP5 and 6 are found in Paneth cells of the gastrointestinal system (Kang et al. 
2014). While human b-defensins (HBDs- 1-4) are produce in epithelial cells of the 
mucosa. Both cathelicidin and b-defensins are in constant surveillance against pathogen 
acting as the first defence barrier (Robert E W Hancock et al. 1998). In some individuals 
the lack of CAMP secretion through the body results with a higher susceptibility towards 
infection. Another feature of CAMPs is characterised by its immunomodulatory capacity, 
for example a-defesins present in neutrophil are responsible to attract T cells expressing 
CD4 and CD8 antigens. b-defensin HBD(1-3) and LL37 is responsible to attract both 
neutrophils, monocytes and T cells to the site of the infection (Zasloff 2002). 
 
 
1.10. Mechanism of action 
 
Several studies with the membrane models were conducted in order to clarify the 
possible mechanism of action of CAMPs. Different models of mechanism associated with 
the interaction between peptides and membrane surface have been discussed and 
proposed over the years. The initial step results in electrostatic interactions between 
cationic peptide and positively charged membrane (Powers and Hancock 2003). 
The carpet mechanism: CAMPs bond to the membrane surface and form a ‘carpet’ 
structure which destabilize hydrophobic interactions of phospholipids. When reach 
critical concentration of peptide the membrane integrity is lost and results in membrane 
disruption (e.g. cecropins, melittin, caerin) (Figure 8A) (Melo et al. 2009). 
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The barrel-stave mechanism: the attached CAMPs aggregate and insert into the 
membrane so that hydrophobic part of the peptide aligns with lipid core region and 
hydrophilic portion of the forms the interior region of the ‘’barrel-like’’ pore (e.g. Pardaxin, 
alamethicin.) (Figure 8B). 
The toroid pore:  CAMPs bind parallel with membrane, hydrophobic residues 
disassociate the polar head group of phospholipids creating a breach in the hydrophobic 
region. Once reach the threshold of peptide-to-lipid ration, CAMPs make a transition to 
perpendicular orientation culminating on toroidal pore (e.g. magainins, protegrins and 
melittin) (Figura 8C) (Brogden 2005). 
 
 
 
 
 
Microbial cell membranes are responsible for many essential functions including 
permeability barrier, oxidative phosphorylation, synthesis of biopolymers and virulence 
A	
B	
C	
Figure	8	-	Schematic	models	of	mechanism	of	action	of	CAMPs.	(A)	The	carpet	mechanism		(B)		The	barrel-stave	mechanism		
(c)		The	toroid	pore.	(adapted	from	Brogden	2005).	
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determinants. The creation of pores contributes to depolarization of the membrane, 
leakage of ions and metabolites which leads to cell death. Although, some CAMPs can 
enter into the cell without disrupting the membrane and then inhibited intracellular targets 
(Yeaman and Yount 2003). 
 
	
	
1.11. Antimicrobacterial potencial 
 
The antimicrobial proprieties of CAMPs hold in future a promising therapeutically 
approach. Many CAMPs are already available in the market as topical drugs such as 
Pexiganan for diabetic foot ulcers, Iseganan for oral mucosaitis, Neuprex for sepsis and 
Omiganan for catheter-associated infections (Hancock and Sahl 2006; Kang et al. 2014). 
Regarding this advances, CAMPs for systemic administration face some obstacles that 
reduced its full effectiveness such as degradation by proteolytic enzymes, low 
bioavailability and inhibition of activity by physiological conditions. Several studies 
present possible solutions with use of non-natural amino acid or D-enantiomer in the 
peptide sequence displaying an increase on stability to the proteases (Ong et al. 2014). 
In addition, delivery approaches with use of synthetic carries, scaffolds (liposomes and 
polymers) and nanoparticles emerged as promising solution to enhance antimicrobial 
activities, decrease toxicities, increase salt stability and reduce protease degradation 
(Schmidtchen et al. 2015). 
Another obstacle facing is the high manufacturing value of large-scale productions of 
CAMPs, about 50 to 400 dollars per gram comparing with antibiotic that only cost 1$ per 
gram. However, different approaches can be used to overcome this problem such as 
chemical synthesis (on solid-phase, solution phase and hybrid) provides the ability of 
incorporate unnatural amino acids (terms of isolation, purification and characterization), 
recombinant DNA, cell-free expression systems (Escherichia coli), transgenic plants 
(Nicotiana benthamiana using viral vectors based on TMV and potato virux X (PVX)) and 
fungi with enhance protein synthesis (da Cunha et al. 2017). The optimization approach 
selected should be carefully considered in the context on the nature of end application 
(e.g. topical or systemic), safety, the degree of antimicrobial potencies required and cost. 
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1.12. CAMPS against Mtb. 
 
The rise of global health concern due to the increased number of multidrug-resistant 
tuberculosis reported has potentiated the research, in order to development of new 
effective drugs. CAMPs show a potential use, for administration as a monotherapy or as 
combined with other drugs. In the present, there is no CAMP admitted to clinical trials for 
the treatment of TB. Although, many studies in vitro and in vivo conducted so far have 
demonstrated inherent antimicrobial activity against either Mtb or MDR-TB. Some 
examples of CAMPs against Mtb studies are summarized in Table 2. 
For instance, VpAmp, derivate from Vaejovis punctatus proved effective against both 
Mtb and MDR strain demonstrated a similar MIC range (Ramírez-Carreto et al. 2015). 
Ramón-Garcia et al 2013 tested the MIC of 49 synthetic peptides W-R rich against Mtb 
presenting a 90 % decrease with 1,1 µM (Ramón-García et al. 2013). The LL-37 and 
CRAMP derivate peptides, in vivo, were successful in reducing the loads in the lungs of 
both Mtb and MDR-TB strain, at 32 g/mouse reduced 53% and ate 32 ug/mouse reduced 
45%, respectively (Rivas-Santiago et al. 2013). The synthetic IK8-all D proved an 
inhibition of growth in Mtb strain with the MIC of 15,6 mg/L (Ong et al. 2014). Yun Lan 
and co-workers, observed the benefits of combining synthesis D-LAK with INH which 
resulted in decreased of MIC of 10 µg/mL (INH) + 6.25 µM of peptide against MDR-TB. 
Linking the effect of D-LAK in the permeability of the cell membrane which facilitates the 
entrance of INH (Lan et al. 2014). Moreover, CAMPs usually present cytotoxicity to the 
host and sensibility to protease degradation. Jiang and co-works found that incorporation 
of D-enantiomers into LL37 resulted in less haemolytic effect (Jiang et al. 2011). 
In general, CAMPs have shown bactericidal activity even though the acquisition of 
resistance towards CAMP as been observed, this is unlike to happen since drastic 
modifications of the bacterial membrane compromise its role. 
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Table	2	-	Examples	of	AMPs	showing	in	vitro	or	in	vivo	activity	against	M.	tuberculosis	and	respective	mechanisms	of	action.	
CAMPs Procedures/MIC determination Activity Citoxicity References 
W-R rich 
peptide PL –
(A-D): 
PL-A SPOT 
technology 
PL(B-D)     
standard 
manual Fmoc 
SPPS 
 
Medium: MB 7H9 modify (without cations) 
PL-(A-C) REMA 
PL-D luciferase-based assay 
MIC90: MTB range 1.1 – 141 µM TPH-1 cells IC50: range 24,3 – 
197,2 µM 
(Ramón-García et al. 
2013) 
 
D-LAK 
family 
Standard 
manual Fmoc 
solid state 
chemistry 
Medium: MB 7H9Broth+10%OADC Broth 
microdilution method 
Incubated 37º 4 up to 6 weeks. Visualized with 
Light microscope. 
MIC90: 
Mtb(SLMS): 25µM 
MDR(GB2): 5µM 
XDR(WYC-I1): 100µM 
Combinatory treatment MIC90: 
MDR:10µM(INH)+6.25 µM 
 
TPH-1 cells 
differentiated into 
macrophage-like 
14.4-32.3 
µM 
(Lan et al. 2014) 
 
VpAmp 
(peptide 
from 
Vaejovis 
punctatus) 
Purchased 
(no data) 
Medium:MB 7H9+10%OADC 
Peptide concentration: 0,4-96,4 µg/mL 
Incubated 37º for 5 days. 
REMA 
MIC90: 
Mtb: 5.4-21.4µM 
MDR: 4.8-30.5µM 
Blood sample 
Eryhtocytes 
9.2-167 
µM 
(Ramírez-Carreto et al. 
2015) 
Synthetic 
(LLKK)2 
Purchased 
(GL biochem) 
Medium: MB 7H9+10%ADC+ 
0.05%Tween+ 
0.2%glycerol 
Broth microdilution method (3.9-500 mg/L) of 
peptides 
spectrophotometrically 
Mic99: 
Mtb: 125-500mg/L 
MDR(CSU87): 62.5-500mg/L 
rRBCs >1000 
mg/L 
(Khara et al. 2014) 
 
Lassomycin Isolated from 
actinomycetes 
Medium: MB 7H9+10%ADC 
Broth microdilution method 
Incubated 37º for 5-7 days 
SynergyMX plate reade 
MIC99: 
Mtb: 0.41-0.83µM and 0.83-
1.65µM 
MDR: 0.83-1.65µM 
XDR: 0-41-165µM 
 
NIH 3T3, and HepG2 350µg/mL (Gavrish et al. 2014) 
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D-V13K, 
D- and L-
LL37 
Standard 
solid-phase 
peptide 
synthesis t-
Boc 
Medium: MB 7H11 
 
Incubated 37º 7 days 
CFU/mL 
MIC99: 
D(1-5) 
Mtb: 35.2-200µg/mL 
MDR: 49-100µg/mL 
D-LL37 
Mtb: 200µg/mL 
erythrocytes D(1-5): 3.5 -
421.5µg/mL 
L-LL37: 43.4 
µg/mL 
D-LL37: 125 
µg/mL 
(Jiang et al. 2011) 
 
Peptoid 1 
1-C134mer 
1-
Nssb,14mer, 
1-11mer, 
1-Pro9 
 
Standard 
solid-phase 
peptide 
synthesis 
 
MABA by NIH/NIAID-contracted laboratory 
 
 
MIC99: 
Mtb: 1-C134mer more active 6.6 
µM and 
1-Nssb infective >100µM 
 
 
RAW 264.7 
and J774 mouse 
macrophage cell line 
 
1-C134mer: 
>100µM 
1-11mer, 1-Pro9: 
50µM 
Peptide 1: 20µM 
1-Pro9, 14mer: 
non toxic 
 
(Kapoor et al. 2011) 
 
11 Tic-Oic 
family 
peptides 
Purchased 
Standard 
solid-phase 
peptide 
synthesis 
Medium: MB 7H12 Broth 
Broth microdilution method (0.5-100µg/mL) of 
peptides 
MIC: Visualise 
MIC99: 
Mtb: 4.92-40.75µM 
MDR(CSU45): 4.92-49.26µM 
Mtb(oflo): 4.92-49.26µM 
------- ------ (Hicks 2016) 
 
PG-1 from 
porcine 
leukocytes, 
HBD-1 
Standard 
solid-phase 
peptide 
synthesis, 
(automated 
Milligen 9050 
peptide 
synthesizer) 
Medium: MB 7H9 
Broth microdilution method 2-fold dilution (0-
128µg/mL) of peptides 
CFU/mL 
PG-1 
Mtb: 128µg/mL (96.7%) 
MDR(RM22): 128µg/mL 
HBD-1(45.1%) 
Mtb: 128µg/mL (49.9%) 
MDR(RM22): 128µg/mL (45.1%) 
 
---- ------ (Fattorini et al. 2004) 
 
Callyaerins 
Cyclic, 
Peptides 
Extraction and 
Isolation from 
Callyspongia 
aerizusa 
Medium: MB 7H9+ 
0.5%glycerol+ 
0.05%Tyloxapol+10% ADS 
Incubated 6 days 
REMA 
MIC90 
Mtb: 2-40µM 
MIC100 
Mtb: 6µM-100µM 
THP-1 and MRC-5 
cell lines 
THP-1: 30-100µM 
MRC-5: 2->100µM 
(Daletos et al. 2015) 
 
lacticin 3147 
nisin A 
Purified Medium: MB 7H9GC broth 
Broth microdilution method 0.5 dilution (0.11-
60mg/mL) of peptides 
MABA 
MIC90 
lacticin 3147 
Mtb: 7.5mg/mL 
nisin A 
Mtb: >60mg/mL 
 
----- ------ (Carroll et al. 2010) 
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HNP-(1-3) 
sNP-1 
PG-1 
All Purified 
exception of 
sNP-1 
synthetize by 
Fmoc 
chemistry 
Medium: MB 7H9 
 
Incubated 37º for 48 hours 
Standard colony count assay 
HNP-(1-2),sNP-1 
Mtb: 50µg/mL (99%) 
HNP-3 
Mtb: 50µg/mL (98%) 
PG-1 
Mtb: 50µg/mL (91,6%) 
HNP-1, sNP-1, PG-1 
Mtb(ci): 50µg/mL (86.3 to 99%) 
------ ------- (Miyakawa et al. 1996) 
 
LL-37 
CRAMP 
E2(Bac8c) 
E6(Sub3) 
CP26 
 
Standard 
solid-phase 
peptide 
synthesis 
(tBOC) 
Medium: MB7H9+ 
10%OADC 
Two-fold serial dilution (0.4–12.8 _g/mL) 
Incubated 37º for 5 days 
REMA 
MIC99 
CP26 Mtb: 2.1µg/mL 
E2 Mtb: 2.6µg/mL 
E6 Mtb: 3.2µg/mL 
LL37 Mtb: ~5µg/mL 
CRAMP Mtb: ~4µg/mL 
In vivo Mtb: ~53% killing at 
32μg/mouse (3xper week, 28-
day treatment) 
In vivo MDR: ~45% killing a 32 
μg/mouse (3x per week, 28-day 
treatment) 
------ --------  
(Rivas-Santiago et al. 
2013) 
 
Magainin I 
Mastoparan 
Cecropin B 
MIAP 
standard 
solid-phase 
peptide 
synthesis 
Medium: MB 7H9+ 10%ADC 
 
Two-fold serial dilution (6,4-1200ug/mL) of 
Peptides 
Incubated 37º for 4 days 
 
MTT assay 
MIC99 
Cecropin B, Mastoparan 
Mtb: 600µg/mL 
Magainin I 
Mtb: 1200µg/mL 
Mtb(clinical isolates): 
MIAP 
Mtb: 300µg/mL 
----- ------  
 
 
(Santos et al. 2012) 
 
vgf-1 Isolated from 
Naja atra 
venon 
Medium: MB 7H12 TB 
 
Bactec TB-460 
MIC99 
MDR (clinical isolates): 8.5 
mg/mL 
----- ----- (Xie et al. 2003) 
 
Ecumicin Isolated from 
actinomycete 
extracts 
Medium: 7H12+ glycerol+ Casitone+ OADC 
MABA 
MIC99 
Mtb: 0,16-0,36 µM 
Mtb(MR): 0.12-0.31µM 
MDR(clinical isolates): 0.31-
0.62µM 
Vero cells (ATCC 
CRL-1586) 
J774.1 macrophage 
cell line 
Vero cells: >63µM 
J774cells: >32µM 
(Pearson et al. 2016) 
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IK8-all D 
IK8-2D 
IK12-all L 
Purchased 
(GL Biochem) 
 
Two fold dilutions (3.9-500mg/L) of peptide Mtb(clinica isolates): 15.6-
62.5mg/L 
RAW264.7 and WI-38 
cells 
HC10: 
>125 to >2000 mg/L 
(Ong et al. 2014) 
 
PR-39 
 
Isolated from 
porcine 
intestine 
Rest 
Synthetic 
Medium: MB 7H12 
BACTEC radiometric assay and 
Standard colony count assay activity of PR-39 
Incubated 37º for 21 days 
PG-39 
Mtb: 50mg/L 80% 
MDR(P1380/94): 100mg/L 50% 
 
----- ----- (Linde et al. 2001) 
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1.13. Cinnamic acids 
 
Cinnamic acids (example for trans-cinnamic acid in Figure 9) belong to the class of 
phenolic acid and it’s considered one of the most secondary metabolites in plants (Xu et 
al. 2009). These secondary metabolites are crucial to plant growth, development, 
reproduction and disease resistance. From spice cinnamon, Cinnamomum zeilanicum 
derives the denomination of cinnamic, use as food condiment, stimulant and antibacterial 
and antifungal compound. Not only is present in cinnamon but also is present in a 
diversity of aliments such as coffee, apples, berries, potato and more. Recently, the 
research on the potential proprieties of cinnamic acids has increased, and more articles 
are being published with potential application in cancer, malaria, diabetes and 
tuberculosis. In addition, molecular hybridization of cinnamic acid with a selective drug 
has been used in order alter the spectrum of potency and activity. 
 
 
 
 
 
 
 
 
 
 
 
1.14. Cinnamic acids agaisnt Mtb 
 
In 1893, Landerer discovered the therapeutic potential of cinnamic acid in TB conducting 
an experiment by injecting emulsion form of cinnamic acid in TB patients. Intravenous 
injections were administrated twice a week for 3 months. Landerer work showed no effect 
on acute TB in young adults. Although, in cases of chronic TB patients a gradual 
improvement of the symptoms was observed. Landerer reported, from the 50 patients 
treatment, a 58 percentage of cure and 20 percentage of improvement and 20 
percentage of death (Warbasse 1894). 
More recent studies tested natural and synthetic cinnamic acid derivates against Mtb  
(Tanachatchairatana et al. 2008). For example, studies conducted by Andrade-Ochoa 
and co-workers reported the capacity of cinnamic acid and cinnamaldehyde against Mtb 
with associated MICs of 8.16 µg/m and 3.12 µg/mL, respectively (Andrade-ochoa et al. 
Figure	9	-	Molecular	structure	of	trans-cinnamic	acid. 
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2015). 
Yoya at 2009, observed the consequences of punctual additions synthetic cinnamic acid 
derivates against TB. Was noticed that some modifications contributed to the decrease 
of activity and other had significant improvements such as the introduction of geranyl 
chain attributing a MIC of 0.6 µg/mL (Yoya et al. 2009). 
Molecular hybridization of cinnamic acid with a selective drug is presented as a solution 
in order to achieve a more efficient compound (Guzman 2014; Slavchev et al. 2014). For 
example, the molecular hybridization of INH with trans-cinnamic acid against Mtb 
resulted in MIC of 3.12 µg/mL (Carvalho et al. 2008). Patel et al. at 2014, used a 
molecular hybridization of piperazine ring into cinnamic acid derivate which leads to 
increase on bioavailability and the antitubercular activities (Patel et al. 2014). 
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1.15. Solid Phase Peptide Synthesis (SPPS) 
 
 
Merrifield, in 1963 introduced Solid Phase Peptide Synthesis (SPPS), a brand new 
method of synthesizing peptides that have enormous advantages relative to the 
previously known. The SPPS methodology has proved to be faster, simpler, cheaper and 
more efficient. 
The peptide is synthesized on an insoluble solid support being one of the most 
determinant factors to build the desire peptide sequence. The reaction vessel is 
connected with a vacuum system which allows the removal of side products and excess 
of reagents and solvents through washing with Dichloromethane (DCM) and 
Dimethylformamide (DMF) and filtration. 
Briefly, SPPS starts with the coupling of an amino acid N alfa protected into the solid 
support (resin). The remaining α-amino acids (AAn) of the sequence are sequentially 
linked together through the formation of an amide bond (peptide bond). After each 
coupling, the reactivity of the alfa-amino group is protected by a temporary protecting 
group (usually 9 fluorenylmethoxycarbonyl (Fmoc)) and the other reactive functional 
groups in the amino acid are blocked by ‘’permanent protection (tert-butyl, tBu). The 
carboxyl group of the amino acid is blocked by the bond linking the solid support or by 
the peptide bond. 
SPPS is characterised by a group of coupling reactions favoured with activation of the 
carboxyl group through coupling agent and deprotection reactions with deprotection of 
the reactive alfa-amide group of the already linked amino acid. Otherwise, in the coupling 
reaction an unwanted acid-base reaction will happen resulting with the formation of a 
salt, instead of bonding the two amino acids with amide bond. 
Another particularly of SPPS, is the sequence order of amino acids, assembled through 
Ct à Nt which is the opposite of biosynthetic route for peptides synthesis observed in 
nature (Nt à Ct sense). The resin not only serve as a peptide support but also as 
protective group of carboxyl amino acid C-terminal. 
The elongation of peptide chain occurs through repetitive cycles of coupling reactions of 
protected amino acid and subsequent deprotection of the temporary protecting group 
(Figure 10). 
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When the sequence is completed all permanent groups are removed and the peptide is 
cleaved from by chemical solution capable of breaking the bond with the solid support. 
Nowadays, the SPPS methodology was quickly and easily automated and new 
equipment were developed in order to produce fast and more efficiently. One example 
of these equipment’s is the Symphony X Multiplex Peptide Synthesizer, developed by 
Protein Technologies, Inc.©, which is a 24-channel peptide synthesizer that can run 
different sequences, scales and protocols on multiple reactors all at the same time, or 
run up to 12 reaction vessels with preactivation (BACHEM 2014; Behrendt, White, and 
Offer 2016). 
 
 
 
 
 
 
Figure	10	-	General	scheme	of	SPPS.	X=O,NH;	AA=	amino	acid;	PG=protecting	group;	TPG=temporary	group;	P	-	resin. 
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2. Materials and Methods 
 
2.1. Reagents, Solvents and Equipment 
 
In this work the reagents and solvents were acquired from Novabiochem (Fmoc-Rink 
Amide MBHA resin and Fmoc-amino acids), Sigma-Aldrich (coupling agents, piperidine, 
N, N-Diisopropylethylamine (DIAE)), Resazurin (n-1-naphthylethylenediamine 
dihydrochloride), Merck  (TFA, solvents). 
Peptides were characterized by mass spectrometry (LC/MS), on Finnigan Surveyor 
LCQ-DECA XP MAX. The purification step of peptides achieved by Reverse Phase 
Medium-Pressure Liquid Chromatography (RP-MPLC), using a C18 Vydac® 218TP 
stationary phase, by Grace Vydac. The purity of the peptides was determined by high-
performance liquid chromatography (HPLC) on a Merck-Hitachi LaChrom Elite 
equipment, with a quaternary pump, automatic and thermostated by Peltier effect injector 
and a diode detector. A reverse phase Purospher star RP C-18 (octadecylsilane) column 
(125 x 4.0 mm), with a particle diameter of 5 μm, was used. The elution was performed 
with a variable gradient of acetonitrile (ACN) in water containing 0.05% trifluoroacetic 
acid (TFA), at a 1 mL/min flow. 
The purified peptides were lyophilized in a BenchTop Pro 9L with omnitronics from SP 
Scientific (Department of Chemistry and Biochemistry of Faculty of Sciences of 
University of Porto). 
 
 
2.2. Peptide Synthesis by SPPS 
 
2.2.1. Manual Synthesis developed in this Project 
 
The SPPS reactor consisted in a cylindrical vessel (polypropylene syringe) with a 
polyethylene porous filter adapted to a vacuum system essential for removal of the 
excess of reagents from the wash, deprotection and coupling steps. A Teflon rod used 
to manually stir the resin beads (Figure 11). 
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2.2.2. Preparation of the resin 
 
The resin chosen as a support for the manual synthesis was the Rink Amide MBHA resin 
LL (100-200 mesh), a polystyrene-based polymer functionalized with 4-
methylbenzhydrylamine (MBHA) groups, further modified with an N Fmoc protected 
(R,S)-2-{4-[amino(2,4 dimethoxyphenyl)methyl]phenoxy} acetic acid linker (Rink-amide 
linker). The loading capacity of the resin was 0,38 mmol/g and syntheses was performed 
at 0.2 mmol scale, so 0.526g of resin was weigh and transferred into the syringe. The 
swelling step of the resin was made by the addition of N,N-dimethylformamide (DMF) 
with continuous stir. After 20 min, DMF was rejected, and followed by the addition of 
dichloromethane (DCM) for 15 min. Before the peptide synthesis, initial removal of Fmoc 
group was performed using 20% piperidine in DMF (3mL, 1x1min + 1x20min). After 
deprotection, the resin was washed with DMF (3mL,3x1 min) and DCM (3mL, 3x1 min) 
and a Kaiser test was performed. 
A Kaiser test positive (dark blue resin beads and solution) indicate that the construction 
of the peptide sequence can be initiated. 
 
Teflon	rod	
Cylindrical	vessel	
Porous	filter	
Vacuum	system		
Figure	11	-	Manual	SPPS	development	in	this	project. 
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2.2.3. Kaiser Test 
 
The Kaiser Test is used to detect the presence of primary amines, determining if coupling 
or deprotection reactions are complete. Ninhydrin (yellow) reacts with the deprotected 
N- terminal amine group leading to the formation of an intense blue chromophore known 
as Ruhemann’s purple (Figure 12). The tests were performed by transferring few beads 
to a small glass tube which was added 6 drops of reagent A and 2 drops of B (3:1). The 
reagent A consisted in a solution of phenol (40 g) in 10 mL of ethanol mix with a solution 
of aqueous KCN (16.5 mg/25 mL) in 100mL distilled pyridine. The reagent B consisted 
of a solution of 5 g of ninhydrin in 100 mL of ethanol. After homogenization, the test tube 
was incubated at 110ºC for 3 min. When N-Fmoc protected amino-acid is present after 
coupling step ninhydrin, and the result should remain yellow (negative test). When the 
test indicated a step wasn’t completed, that step was repeated (Kaiser et al. 1980). 
 
	
Figure	12	-	Ninhydrin	reaction	with	primary	amines,	resulting	in	the	formation	of	chromophore	(deep	blue).	
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2.2.4. Coupling of Amino Acids and Deprotection Cycles 
 
The Elongation step is characterized by the coupling of an amino acid to the peptidyl-
resin. Before being transferred to the syringe vessel the amino acids were activated for 
5 min by a solution of Fmoc-AA-OH (5 eq.), coupling agent O-(benzotriazol-1-yl)-
N,N,N′,N′- tetramethyluronium hexafluorophosphate (HBTU, 5 eq.) and base DIEA (10 
eq.) in DMF. The activated amino acid solution was transferred to the syringe to react 
with the previously deprotected resin or peptidyl-resin for 1 hour with continuous stirring. 
Once the coupling was completed, the peptidyl-resin was washed with DMF (3 mL, 3 x 
1 min) and DCM (3 mL, 3 x 1 min) and Kaiser test was performed. When the test result 
came negative (yellow) was followed by the deprotection step applying the deprotection 
solution consisted in 20% of piperidine in DMF (3 mL, 1 x 1 min + 1 x 20 min). After this 
time, the resin was washed with DMF (3 mL, 3 x 1 min) and DCM (3 mL, 3 x 1 min) and 
another Kaiser test was made. Confirmed positive (dark blue) the next Fmoc-AA-OH was 
coupled following the previously described method.  The peptide sequence was 
achieved by repeating the cycles of coupling of N-Fmoc amino acids and deprotection 
steps. 
 
 
2.2.5. Structural modification of CAMPs 
 
After the peptide sequence completed, the peptidyl-resin for each peptide was divided 
into two fractions. The fraction CAMP(n) remained untouched and the fraction 
Cin+CAMP(n) was modified/coupled with cinnamic acid derivate. Deprotection of the 
Fmoc-AA-OH of the fraction Cin+CAMP(n) with 20% of piperidine in DMF (3mL, 1 x 1 
min + 1 x 20 min). When finished cinnamic acid derivate was coupling to the sequence 
through activated solution of coupling agent cinnamic derivate, N,N,N′,N′-Tetramethyl-
O-(benzotriazol-1-yl)uronium tetrafluoroborate (TBTU,) and base DIEA (10 eq.) in DMF 
for 3 hours with continuous stirring. The Kaiser test was performed and with a negative 
result, peptide modification was completed. 
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2.2.6. Cleavage and deprotection of side chairs of the peptide 
 
When the peptide was completed and with a final deprotection step, the peptidyl-resin 
was subjected to a cleavage cocktail in order to break the bond linking the peptide to the 
resin support. In the hood was prepared a cleavage cocktail, containing 95 % TFA,  2.5% 
TIS (Triisopropylsilane)  and 2,5% H2Odd. Then the dry peptidyl-resin was transferred to 
15 mL Falcon tubes in 100 mg portions and 1 mL of cleavage cocktail was added to each 
Falcon. The tubes were left under orbital stirring for 2h at room temperature. When 
finished, the contents of tubes were filtered on funnel previously rinsed with TFA, and 
the resin beads were washed with TFA. The filtrate, containing the soluble peptide, was 
transferred to new 15 mL Falcon tubes in 1 mL portions and 14 mL of cold tert-butyl 
methyl ether were added to each tube. The peptide containing tubes were stored at -22 
ºC for 30 min. After this time the tubes were centrifuged at 3500 rpm for 5 minutes at -5 
ºC then the ether was rejected and other 14 mL of cold ether was added. The addition 
of ether and centrifugation were repeated 3 more times and finally, the tubes were left in 
a vacuum desiccator until the crude peptide was dry. Dry peptide pellets were then 
solubilized in 10% aqueous acetic acid and analysed by HPLC and LC-MS. 
 
2.3. Purification of the conjugates 
 
CAMP(n) and CAMP(n) conjugates (Cin+CAMP(n) were solubilized in 10% aqueous 
acetic acid and purified by RP-MPLC, using ACN in water with 0.05% TFA as eluent, in 
gradient mode (15 – 35%). The collected fractions were analysed by HPLC to determine 
which contained the conjugate with a purity greater than 92%. These fractions were 
subsequently pooled, lyophilized and stored at -22ºC until use. 
 
 
2.3.1. Antimicrobial peptides 
 
Peptide amino acid sequences were based on peptides with 9 amino acid of length 
previously describe and analysed in Ramon-Garcia (2013) study which included 
peptides enriched W and R for higher activity against Mtb (Ramón-García et al. 2013). 5 
structurally similar CAMP(n) (Table 3) were synthesized using standard manual Fmoc 
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SPPS by above methodology already described. In order to improve CAMP(n) activity, 
a modification in the N-terminal side was performed with the coupling of a cinnamic acid 
derivate (Table 4). 
Peptides were weighed and diluted in sterile distilled water to obtain the final stock 
concentration and then store 4ºC until use. 
 
 
 
Table	3	-	Sequence	of	synthesized	CAMP(n)	in	this	project.	
CAMP(n) Sequence Structure 
 
 
 
CAMP1 
 
 
 
WKWLKKWIK 
 
 
 
 
CAMP2 
 
 
 
WRKFWKYLK 
 
 
 
 
CAMP3 
 
 
 
RLWWWWRRK 
 
 
 
 
CAMP5 
 
 
 
RIRRWKFRW 
 
 
 
 
CAMP7 
 
 
 
RQRRVVIWW 
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Table	4	-	Sequence	of	synthesised	Cin+CAMP(n)	in	this	project.	
Cin+CAMP(n) Sequence Structure 
 
Cin+CAMP1 
trans cinnamic +WKWLKKWIK 
 
 
Cin+CAMP2 
p-methoxycinnamic +WRKFWKYLK 
	
 
 
Cin+CAMP3 
3,4-
Dimethoxycinnamic+RLWWWWRRK 
 
 
Cin+CAMP5 
o-Nitrocinnamic+RIRRWKFRW 
 
 
 
Cin+CAMP7 
trans cinnamic +RQRRVVIWW 
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2.4. In vitro assays 
	
 
2.4.1. Mycobacterial strains, growth conditions and inoculum preparation 
 
M. tuberculosis H37Rv susceptible strain and resistant clinical isolate MDR-Tb 
(resistance to INH, RIF and STR) were used at Instituto Nacional De Saúde Dr Ricardo 
Jorge (INSA) reference laboratory, all studies conducted in a laboratory of level 3 of 
biosecurity based on international procedures of manipulation this class of 
microorganisms. 
Cultures were grown in Lowenstein-Jensen (LJ) medium for 21 days at 37ºC. 
The inoculum was prepared by scraped bacteria from different parts of LJ medium slants 
in order to ensure diverse population (Woods et al. 2011). Then the scraped bacteria 
were transferred into a tube containing 15-20 glass beads and were vortexed for 1-2 min. 
Right away was added sterile distilled H2O into the tube, vortexed for 1-2 min and 
solubilize bacteria was transferred into a new tube. The turbidity of the supernatant was 
adjusted to McFarland 1.0 (approximately 3 x 108 CFU/mL). 
 
2.4.2. Preparation of Resazurin 
 
Resazurin powder (n-1-naphthylethylenediamine dihydrochloride) was dissolved in 
sterile distilled water to a final concentration of 0.05 mg/mL and stored at 4 ºC until use. 
 
2.4.3. Anti-Mycobacterium tuberculosis assays 
 
The antibacterial activities of 5 CAMP(n) and 5 Cin+CAMP(n) against Mtb were assayed 
by the Resazurin Microtiter Assay Plate (REMA) method. Two different clinical isolates 
were used: (i) drug susceptible strain H37Rv; (ii) MDR strain patient clinical isolate. Their 
antibiograms were determined using the BD BACTEC™ MGIT™ method at INSA. 155 
µL (peptides and positive control) and 180µL(negative control) of modify Middlebrook 
7H9 médium (BD BBLTM MGITTM) supplemented with 10% Middlebrook OADC (oleic acid 
0.6g, bovine albumin 50g, dextrose 20g a catalase 0.02g (BD BBLTM MGITTM OADC) 
was added in each well of 96 well-plate (polystyrene, Sigma-Aldrich). Serial two-fold 
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dilutions of the peptides were prepared in 25 μl of sterile distilled water (0.25 µg/mL to 
128 µg/mL) and 20 µL of bacterial suspensions were added to the well making a final 
volume of 200 µL . Negative control with untreated bacteria, and positive control with INH 
(1.04 µg/mL) MDR-TB strain used INH+STR (10.38 µg/mL) were used (Figure 13). The 
plates of Mtb h37Rv and MDR-tb were incubated for 7 and 14 days, respectably, at 37°C. 
The growth of Mtb in the presence of peptides was visualized on a light microscope. 
After, 25 µL of the resazurin solution were added per well, followed by another incubation 
overnight at 37°C. A change of color of resazurin from blue to pink indicated its reduction 
to resorufin, and therefore the growth of microorganisms. The MIC that inhibited 50 and 
90% of bacterial growth compared with the growth control, was determined for each 
peptide by visual inspection and by further assure with resazurin reaction.  All peptide 
concentrations were tested by duplicate. 
 
 
 
 
 
 
 
 
Negative	control		
Positive	control		
Figure	13	-	schematized	the	96	well-plate,	was	performed	serial	two-fold	dilutions	(0,25-128	µg/mL);	CAMP(n):	
CAMP	without	modification	N-terminal;	Cin+CAMP(n),	CAMP	with	modification	in	N-terminal	coupling	cinnamic	
acid;	Positive	control	(180µL	medium	+	20µL	bacterial	suspension	+	1.04	µg/mL).	
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2.5. Cell culture 
 
THP-1 human monocyte cell line were used as a macrophage model. Undifferentiated 
TPH-1 cells were maintained in RPMI-1640 medium supplemented with 10% fetal calf 
serum (FCS) and posterior differentiated into adherent macrophages by exposure to 80 
ng/mL phorbol-myristate actate (PMA) for 24 h prior to experiment. 
 
2.6. Cytotoxicity assay 
 
The cytotoxicity of the 5 CAMP(n) and 5 Cin+CAMP(n) was determined by the MTS (3-
(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium) Tetrazolium assay, which measured the cell viability, based on article 
(Ramón-García et al. 2013).  The differentiated THP-1 cells were seeded in 96-well 
plates at a cell density of 4x103 cells/well. The peptides were diluted (concentration range 
0.0156 µg/mL-256 µg/mL) in RPMI-1640 medium supplemented with 10% FCS and then 
were incubated with differentiated THP-1 cells at 37 ºC, 5% CO2 for 24 h. Then the cells 
were incubated with MTS solution containing phenazine ethyl sulphate (0.21 mg/mL) per 
well for 4h at 37º to convert the tetrazolium to the soluble formazan product. The 
experiments were performed two times (Riss et al. 2013).  
 
 
2.7. Statistical analysis 
 
All data presented in this study were statistically analysed using program Prism 
(GraphPad Software). One way or two-way ANOVA. All experiments were performed at 
least twice. 
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3. Results 
 
3.1. Peptide synthesis and characterization 
 
3.1.1. CAMP1 
 
Once crude of CAMP1 was dried in the vacuum desiccator and then solubilized in 10% 
aqueous acetic acid, was analysed by HPLC (Figure 14) and LC-MS (Figure 15). HPLC 
analysis demonstrated a distinct main compound (retention time (rt)=11.7 min) 
The exact and observed molecular mass of CAMP1 were 1313.8 Da and 1314.67 g/mol, 
respectively confirmed the target peptide (Table 5) as [peptide + H]. It is possible to 
observe several peaks in the mass spectrum, corresponding to different protonation 
states of the peptide. 
 
	
Figure	14	–	Chromatogram	of	the	product	of	the	manual	synthesis	of	the	peptide	CAMP1,	acquired	with	a	HPLC	
system,	with	a	C18	column,	using	ACN	 in	water	with	0.05%	TFA	as	eluent,	 in	gradient	mode	(0	–	100%),	 for	30	
minutes,	at	a	flow	of	1	mL/min	and	detection	at	λ	=	220	nm. 
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Figure	15	-	Mass	spectrum	(LC-ESI/Orbitrap	MS,	positive	mode)	of	the	peptide	CAMP1	(manual	synthesis). 
 
3.1.2. CAMP2 
 
The synthesis of compound CAMP2 was carried out as described in the Experimental 
Section. The isolated product was analysed by HPLC and by LC-MS. The resulting 
chromatogram and mass spectrum are represented in Figure 16 and Figure 17, 
respectively. The HPLC chromatogram revealed the formation of a major product, with 
a rt of 11.3 min, LC-MS analysis confirmed this product to have the molecular mass 
expected for compound of 1354,73 g/mol (Table 5). 
 
	
Figure	16	-	Chromatogram	of	the	product	of	the	manual	synthesis	of	the	peptide	CAMP2,	acquired	with	a	HPLC	
system,	with	a	C18	column,	using	ACN	in	water	with	0.05%	TFA	as	eluent,	in	gradient	mode	(0	–	100%),	for	30	
minutes,	at	a	flow	of	1	mL/min	and	detection	at	λ	=	220	nm.	
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Figure	17	-	Mass	spectrum	(LC-ESI/Orbitrap	MS,	positive	mode)	of	the	peptide	CAM2	(manual	synthesis). 
 
3.1.3. CAMP3 
 
The sequence and exact mass of the peptide CAMP2 by LC-Ms (Figure 18). The HPLC 
chromatogram confirmed the formation of a main product, with rt = 12.3 min (Figure 19), 
which was identified as the target peptide CAMP3 by LC-MS analysis presenting the 
expected molecular mass of 1471.80 g/mol (Table 5). 
 
 
	
Figure	18	-	Chromatogram	of	the	product	of	the	manual	synthesis	of	the	peptide	CAMP3,	acquired	with	a	HPLC	
system,	with	a	C18	column,	using	ACN	 in	water	with	0.05%	TFA	as	eluent,	 in	gradient	mode	(0	–	100%),	 for	30	
minutes,	at	a	flow	of	1	mL/min	and	detection	at	λ	=	220	nm. 
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Figure	19	-	Mass	spectrum	(LC-ESI/Orbitrap	MS,	positive	mode)	of	the	peptide	CAMP3	(manual	synthesis). 
 
3.1.4. CAMP5 
 
HPLC analysis revealed a light complex crude compound although the main peak (rt = 
11.2 min), whose LC-MS analysis confirmed as the target peptide, which has an exact 
mass of 1401,8 Da (Table 5) (Figure 20 and 21). 
 
	
Figure	20	-	Chromatogram	of	the	product	of	the	manual	synthesis	of	the	peptide	CAMP5,	acquired	with	a	HPLC	
system,	with	a	C18	column,	using	ACN	 in	water	with	0.05%	TFA	as	eluent,	 in	gradient	mode	(0	–	100%),	 for	30	
minutes,	at	a	flow	of	1	mL/min	and	detection	at	λ	=	220	nm. 
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Figure	21	-	Mass	spectrum	(LC-ESI/Orbitrap	MS,	positive	mode)	of	the	peptide	CAMP5	(manual	synthesis). 
 
3.1.5. CAMP7 
 
The isolated product was analysed by HPLC and by LC-MS, yielding the chromatogram 
and mass spectrum presented in Figure 22 and Figure 23, respectively. Results obtained 
confirmed that CAMP7, whose molecular weight is 1297.80 g/mol, was the larger peak 
of this synthesis (rt = 12.9 min) (Table 5). 
 
	
Figure	22	-	Chromatogram	of	the	product	of	the	manual	synthesis	of	the	peptide	CAMP7,	acquired	with	a	HPLC	
system,	with	a	C18	column,	using	ACN	 in	water	with	0.05%	TFA	as	eluent,	 in	gradient	mode	(0	–	100%),	 for	30	
minutes,	at	a	flow	of	1	mL/min	and	detection	at	λ	=	220	nm. 
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Figure	23	-	Mass	spectrum	(LC-ESI/Orbitrap	MS,	positive	mode)	of	the	peptide	CAMP7	(manual	synthesis). 
 
 
The general peptide products obtained by manual synthesis were a success, it was 
decided to carry out their purification. 
 
 
Peptide Exact mass (Da) Molecular mass 
observed (g/mol) 
Retention time, rt 
(min) 
CAMP1 1313.8 1314.7 11.7 
CAMP2 1353.8 1354.7 11.3 
CAMP3 1471.8 1471.8 12.3 
CAMP5 1401.8 1402.8 11.2 
CAMP7 1296.8 1297.8 12.9 
	
Table	5	-	The	exact	mass	and	molecular	mass	observed	of	the	CAMP(n)	peptides	detected	by	LC-MS	and	retention	
time	determined	by	HPLC. 
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3.2. Structural modification of CAMP with cinnamic derivates  
 
After synthesizing the target peptides, CAMP(n) were modified with an cinnamic acid 
derivate in N-terminal side, as described in the experimental procedure section. Results 
from the syntheses of compounds Cin+CAMP(n) are next described. 
3.2.1. Cin+CAMP1 
Once dried in vacuum desiccator and then solubilized in 10% aqueous acetic acid, 
Cin+CAMP1 was analysed by HPLC (Figure 24) and LC-MS (Figure 25). HPLC analysis 
demonstrated a distinct main compound (rt=15.5 min). 
The exact mass and observed molecular mass of Cin+CAMP1 were 1443.9 Da and 
1444.7 g/mol, respectively confirmed the target peptide (Table 6). 
 
	
Figure	24	-	Chromatogram	of	the	product	of	the	manual	synthesis	of	the	peptide	Cin+CAMP1,	acquired	with	a	HPLC	
system,	with	a	C18	column,	using	ACN	 in	water	with	0.05%	TFA	as	eluent,	 in	gradient	mode	(0	–	100%),	 for	30	
minutes,	at	a	flow	of	1	mL/min	and	detection	at	λ	=	220	nm. 
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Figure	25	-	Mass	spectrum	(LC-ESI/Orbitrap	MS,	positive	mode)	of	the	peptide	Cin+CAMP1	(manual	synthesis).	
	
	
3.2.2. Cin+CAMP2 
 
The isolated product was analysed by HPLC and by LC-MS, yielding the chromatogram 
and mass spectrum presented in Figure 26 and Figure 27, respectively. Results obtained 
confirmed that Cin+CAMP2, whose molecular weight is 1515.7 g/mol, didn’t correspond 
to the larger peak of this synthesis (rt = 14.6 min) (Table 6). 
 
 
	
Figure	26	-	Chromatogram	of	the	product	of	the	manual	synthesis	of	the	peptide	Cin+CAMP2,	acquired	with	a	HPLC	
system,	with	a	C18	column,	using	ACN	 in	water	with	0.05%	TFA	as	eluent,	 in	gradient	mode	(0	–	100%),	 for	30	
minutes,	at	a	flow	of	1	mL/min	and	detection	at	λ	=	220	nm. 
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Figure	27	-	Mass	spectrum	(LC-ESI/Orbitrap	MS,	positive	mode)	of	the	peptide	Cin+CAMP2	(manual	synthesis). 
 
 
Together, these results show that the manual synthesis of Cin+CAMP2 results in a very 
complex combination of different products. The Automated MW-assisted Synthesis in 
the CEM Liberty1 peptide synthesizer of this peptide was performed, but similar results 
(not shown) were obtained. In the purification step was able to isolate the Cin+CAMP2 
into three fractions, the first fraction consisted 100% of p-methoxycinnamic acid without 
double bond, second fraction composed by 50% with double bond and 50% without 
double bond of p-methoxycinnamic acid and last fraction was mainly constituted by 
70.2% with double bond. The quality of the product p-methoxycinnamic acid was found 
to be the problem. Fraction 1 was choose to further antimicrobial test assays. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 									FCUP	
Development	of	new	antimicrobial	peptides	against	Mtb	
	
	
59	
3.2.3. Cin+CAMP3 
 
The HPLC chromatogram confirmed the formation of a major product of Cin+CAMP3, 
with rt = 14.2 min, whose LC-MS analysis confirmed as the target peptide, which has an 
exact mass of 1660.9 Da (Table 6) (Figure 28 and 29). 
 
	
Figure	28	-	Chromatogram	of	the	product	of	the	manual	synthesis	of	the	peptide	Cin+CAMP3,	acquired	with	a	HPLC	
system,	with	a	C18	column,	using	ACN	 in	water	with	0.05%	TFA	as	eluent,	 in	gradient	mode	(0	–	100%),	 for	30	
minutes,	at	a	flow	of	1	mL/min	and	detection	at	λ	=	220	nm. 
 
 
	
Figure	29	-	Mass	spectrum	(LC-ESI/Orbitrap	MS,	positive	mode)	of	the	peptide	Cin+CAMP3	(manual	synthesis). 
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3.2.4. Cin+CAMP5 
 
The synthesis of compound Cin+CAMP5 was carried out as described in the 
Experimental Section. The isolated product was analysed by HPLC and by LC-MS. The 
resulting chromatogram and mass spectrum are represented in Figure 30 and Figure 31, 
respectively. The HPLC chromatogram revealed the formation of a major product, with 
a rt of 12.8 min, LC-MS analysis confirmed this product to have the molecular mass 
expected for compound of 1578.5 g/mol (Table 6 and Figure 31). 
 
	
Figure	30	-	Chromatogram	of	the	product	of	the	manual	synthesis	of	the	peptide	Cin+CAMP5,	acquired	with	a	
HPLC	system,	with	a	C18	column,	using	ACN	in	water	with	0.05%	TFA	as	eluent,	in	gradient	mode	(0	–	100%),	for	
30	minutes,	at	a	flow	of	1	mL/min	and	detection	at	λ	=	220	nm.	
 
	
Figure	31	-	Mass	spectrum	(LC-ESI/Orbitrap	MS,	positive	mode)	of	the	peptide	Cin+CAMP5	(manual	synthesis). 
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3.2.5. Cin+CAMP7 
 
The sequence and exact mass of the peptide Cin+CAMP7 was obtained by LC-Ms 
(Figure 33). The HPLC chromatogram confirmed the formation of a main product, with rt 
= 14.2 min (Figure 32), which was identified as the target peptide CAMP3 by LC-MS 
analysis presenting the expected molecular mass of 1426.8 g/mol see in Table 6. 
 
	
Figure	32	-	Chromatogram	of	the	product	of	the	manual	synthesis	of	the	peptide	Cin+CAMP7,	acquired	with	a	HPLC	
system,	with	a	C18	column,	using	ACN	 in	water	with	0.05%	TFA	as	eluent,	 in	gradient	mode	(0	–	100%),	 for	30	
minutes,	at	a	flow	of	1	mL/min	and	detection	at	λ	=	220	nm. 
 
 
	
Figure	33	-	Mass	spectrum	(LC-ESI/Orbitrap	MS,	positive	mode)	of	the	peptide	Cin+CAMP7	(manual	synthesis).	
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In Table 6 we can observe the exact mass, molecular mass observed and the retention 
time for each peptide obtained, using HPLC.  
 
 
 
	Table	6	-	The	exact	mass	and	molecular	mass	observed	of	the	Cin+CAMP(n)	peptides	detected	by	LC-MS	and	
retention	time	determid	by	HPLC. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Peptide Exact mass (Da) Molecular mass 
observed (g/mol) 
Retention time, rt 
(min) 
Cin+CAMP1 1443.8 1444.8 15.6 
Cin+CAMP2 1513.8 1514.7 14.7 
Cin+CAMP3 1661.9 1662.8 14.2 
Cin+CAMP5 1576.9 1578,5 12.8 
Cin+CAMP7 1426.8 1428.7 14.2 
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3.3. Peptide Purification values. 
	
Each peptide synthetized (CAMP(n) and Cin+CAMP(n)) were purified through RP-MPLC 
(previously described), the results obtained are display in Table 7 and graphic of 
purification analysis present in Supplementary information. 
	
	Table	7	-	Percentage	of	purification	and	amount	of	the	manual	synthesis	CAMP(n)	and	Cin+CAMP(n).	Purification	
step	was	performed	as	previously	described	 in	Experimental	Procedures	by	RP-MPLC	 (purification	analysis	and	
quantification	was	made	by	HPLC,	results	in	Sumplementary	information).	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CAMPs % of Purification Amount (mg) 
CAMP1 99 17.1 
Cin+CAMP1 96.1 24.1 
CAMP2 98 28.4 
Cin+CAMP2 Fraction 1 100 4.4 
Cin+CAMP2 Fraction 2 50 2.3 
Cin+CAMP2 Fraction 3 70.2 3 
CAMP3 97 7.8 
Cin+CAMP3 87.9 3.7 
CAMP5 (1) 79.9 28.4 
CAMP5 (2) 92.2 10.7 
Cin+CAMP5 98 7.7 
CAMP7 100 6.2 
Cin+CAMP7 95.85 6.8 
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3.4. In vitro anti-tuberculosis assay 
 
The in vitro anti-tuberculosis assay of the CAMP(n) and Cin+CAMP(n) were screened 
by visually comparing the growth and the morphology of the mycobacterial colonies with 
the control samples by light microscopy and through REMA method. 
All ten peptides tested in this study showed concentration-dependent antibacterial 
activity against two clinical strains of Mtb (H37Rv and MDR). The results demonstrated 
that the peptides efficiently inhibited bacterial growth at varying MICs, summarized in 
Table 10. In general, all modified CAMPs demonstrated an enhance of the potency when 
compared with CAMP(n) peptides. The peptides with most pronounced activity against 
susceptible Mtb were Cin+CAMP 1 and 3 having a MIC of 44.33 and 38.51 µM, 
respectively, resulting in a 45% increase in the peptide activity (Figure 34) (Table 10). 
	
Figure	34	-	MIC	activities	of	CAMP1,	Cin+CAMP1,	CAMP3,	Cin+CAMP3	against	susceptible	Mtb	expressed	in	µM. 
 
 
In contrast, Cin+CAMP5 appeared to be the least potent modified peptide, with a 
presence of bacterial growth even at 81.17 µM (>128µg/mL). For the CAMP(n) with 
exception of CAMP3, none was capable to stop the bacterial growth even in more than 
90 µM (>128ug/mL). 
At low concentrations of peptide is denoted inhibition of growth with a decreased of 50% 
when compared to the control wells. MIC50 of the most active peptide was 0.69 µM 
(Cin+CAMP1) followed by 2.41 µM (Cin+CAMP3) when compared to the respective 
CAMP1 and CAMP3 the MIC50 was 6.09 µM and 5.44 µM, respectively (Figure 35) 
(Table 8). 
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Table	8	-	Reduction	of	MIC50	of	Cin+CAMP(n)	compared	with	IC50	of	parental	CAMP(n)	against	Mtb.	
Peptides  Cin+CAMP1 Cin+CAMP2 Cin+CAMP3 Cin+CAMP5 Cin+CAMP7 
% of 
Reduction  
88.7 55.3 55.7 55.7 54.6 
	
Figure	35	-	MIC50	activities	of	CAMP(n)	and	Cin+CAMP(n)	against	susceptible	Mtb	expressed	in	uM.	
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With the increased concentration of peptide, the growth of mycobacteria was further 
inhibited and the improvement of antimicrobial activities was observed through 
microscope. The potential inhibited growth effect exhibited were characterised by a 
presence of disperse bacillus instead of remaining as colonies of aggregated 
mycobacteria seen in the control wells, see Figure 36. 
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Notably, against resistant strain of Mtb the antimicrobial potential of the Cin+CAMP1 was 
preserved with MIC of 44.33 µM. The same pattern of improvement in activity with 
cin+CAMP(n) treatment over CAMP(n) treatment was observed, however, CAMP5 was 
the exception reflecting in a considerable increase of antimicrobial activity with 45.7 µM. 
Despite that, Cin+CAMP3 showed the most effective inhibition of growth at low 
concentrations with an MIC50 of 0.6 µM (Figure 37) (Table 9 and 10). 
	
Table	9	-	Reduction	of	MIC50	of	Cin+CAMP(n)	compared	with	IC50	CAMP(n)	against	MDR-TB.	
Peptides  Cin+CAMP1 Cin+CAMP2 Cin+CAMP3 Cin+CAMP7 
% of 
Reduction  
94.3 55.3 77.9 8.3 
 
 
Figure	36	-	In	vitro	anti-TB	screening	of	D-AMPs	activity	against	Mtb	clinical	isolates	susceptible	strain	H37Rv;	Representative	light	
microscope	images	show	the	growth	condition	of	the	bacteria	at	various	concentrations	of	CAMP(n)	and	Cin+CAMP(n)	after	7	days	
of	incubation.	The	framed	images	indicate	the	lowest	concentrations	of	each	peptide	to	inhibit	95%	of	bacterial	growth	compared	
with	the	growth	control	and	further	confirmed	through	REMA	assay.	
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Figure	 37	 - MIC50	
activities	of	CAMP(n)	
and	 Cin+CAMP(n)	
against	 Resistance	
Mtb	 MDR	 (INH,RIF	
and	 STR)	 expressed	
in	µM. 
CAMP 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mtb H37Rv 
 
MDR Mtb 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 MIC 50 MIC 95 MIC 50 MIC95 
 µg/mL µM µg/mL µM µg/mL µM µg/mL µM 
CAMP1 8 6.09 >128 >97.43 64 48.71 128 97.42 
Cin+CAMP1 1 0.69 64 44.33 4 2.77 64 44.33 
CAMP2 8 5.91 >128 >94.55 8 5.91 128 94.50 
Cin+CAMP2 4 2.64 128 84.56 4 2.64 128 84.56 
CAMP3 8 5.44 128 86.97 4 2.72 128 87.00 
Cin+CAMP3 4 2.41 64 38.51 1 0.60 128 77.02 
CAMP5 16 11.41 >128 >91.31 16 11.41 64 45.66 
Cin+CAMP5 8 5.07 >128 >81.17 32 20.29 >128 >81.17 
CAMP7 8 6.17 >128 >98.74 16 12.32 >128 >98.55 
Cin+CAMP7 4 2.80 128 89.71 16 11.21 128 89.71 
Table	10	-	Minimum	inhibitory	concentrations	(MIC)	of	synthetic	peptides	against	Mtb	H37Rv	and	MDR	Mtb	(resistant	to	INH,	
RIF	and	STR)	expressed	in	µg/m	and	µM.	
Figure	37	-	MIC50	activities	of	CAMP(n)	and	Cin+CAMP(n)	against	Resistance	Mtb	MDR	(INH,RIF	and	STR)	expressed	in	µM. 
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3.5. Determination of peptide cytotoxicity 
 
The MTS assay was used to assess the cytotoxicity of the CAMPs.  Initial cytotoxicity 
studies were carried out using macrophage-like THP-1 cells and all peptides showed a 
concentration-dependent cytotoxic effect. Previously tested CAMP(n) IC50 values were 
applied in this study from the reference (Ramón-García et al. 2013). Comparison of the 
EC50 values reveals the Cin+CAMP(n) have a substantially higher cytotoxicity than 
CAMP(n) (Table 11). Significant cytotoxic effects were observed at concentrations of 
7.74µM for Cin+CAMP1 and 17.08µM for Cin+CAMP2 (Table 11) (Figure 38). 
 
Table	11	-	Summary	of	IC50	of	CAMP(n)	and	Cin+CAMP(n)	of	the	MTS	assay	performed	in	THP-1	cells.	Results	are	
an	average	of	two	independent	repeated	experiments.	(1)	Value	of	reference	previously	describe	in	(Ramón-
García	et	al.	2013). 
CAMP IC50 
µg/mL µM 
CAMP1 48.04 24.3(1)/36.57 
Cin+CAMP1 11.17 7.74 
CAMP2 ------ 47.31(1) 
Cin+CAMP2 25.85 17.08 
CAMP3 ------ 87.0(1) 
Cin+CAMP3 40.37 24.29 
CAMP5 ------ 182.5(1) 
Cin+CAMP5 64.33 40.80 
CAMP7 ------ 197.2(1) 
Cin+CAMP7 61.23 42.91 
 
 
 
 
 
 
 
 
 
 
µg/mL	
Figure	38	-	Cytotoxicity	of	CAMP1	and	Cin+CAMP(n)	on	THP-1	cells.		Values	expressed	in	µg/mL,	in	collaboration	with	
University	of	Minho. 
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4. Discussion  
 
The current increase of resistant Mtb strains to conventional antibiotics and poor patient 
compliance for the long and intense treatment has boosted the development of new 
active and less toxic compounds. 
CAMPs arise as a potential candidate of drug-resistant TB for clinical use. This study 
intends to determine and optimize the properties of CAMPs already tested from (Ramón-
García et al. 2013) in order to improve antimicrobial agents, specifically against resistant 
Mtb strains. After the crescent research on cinnamic acid, its antimicrobial activity and 
previous administration as a potential treatment of Mtb in late 19s (Warbasse, 1894), 
was decided to modify CAMPs with the addition of a cinnamic acid derivate in order to 
enhance the antimicrobial potential against Mtb. Briefly, in this study was synthesised 
and determined the antimycobacterial activity of 10 CAMPs which 5 have attached a 
cinnamic acid derivate. 
In the article of the sequence peptide reference, Ramon-Garcia 2013 determined a MIC 
value of 1.1 µM for the most effective and 24.7 µM for the lowest effective of chosen 
peptides. Although with excellent results, the authors recur to modified MB 7h9 medium 
with no salts present (Ca2+, Mg2+ and Na+) known to inhibit the activity of cationic peptides 
at physiologic concentration. In the present work antimicrobial assay was performed with 
unmodified medium with present of cations in order to achieve the physiological condition 
as possible. The in vitro growth and MIC values were obtained by visual inspection and 
REMA assay to assure the results. In general, our results indicated that the presence of 
cations in the medium as a vast consequence on CAMP antimicrobial effect. 
Nevertheless, the copulation of cinnamic acid lend to an improvement on Cin+CAMP(n) 
activities, Cin+CAMP 1 and 3 were the most effective with total inhibition of cell growth. 
MIC50 and MIC90 values observed for those peptides were 0.69 µM and  44.33 µM for 
Cin+CAMP1 and 2.41µM and 38.51µM for Cin+CAMP3. For instances the MIC values 
determined for CAMP1 were 6.09 µM and >97.43 µM and for CAMP2 were 5.44 µM and 
86.97 µM, an almost two-fold increase in concentration level is present. Another positive 
observation was that Cin+CAMP1 and Cin+CAMP3 appear to be equal effective against 
MDR strain. Unfortunately, the incorporation of cinnamic acid derivate into the CAMP(n) 
affect the cytotoxicity towards THP-1 cells and may be associated with a reduction of 
bacterial membrane selectivity after modification. Even though some of the peptide 
tested weren’t effective in complete eradication of Mtb, some observational features in 
cell culture and MIC50 values make Cin+CAMP(n) still a promising compound. 
Normally, in cell culture, the morphology of Mtb appears as aggregated clumps of 
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colonies. The reason is largely because of the widely complex mycobacterial cell wall 
rich in mycolic acids. In this study was observed that all Cin+CAMP(n) and some of 
CAMP(n) which not allows the formation of aggregates of colonies. A dispersion and 
scattered like effect was observed in all treated cultures with the exception of INH and 
STR. This behaviour may be explained due to the amphipathic properties of CAMPs.  
Which appears to affect the composition of the cell envelope and reduce virulence of Mtb 
in high concentrations of CAMP. Another two studies (Lan et al. 2014; Vermeer et al. 
2012) described the same physiologic behaviour by antimicrobial peptides. 
This should be taken in consideration due to the considerable differences in cell wall 
thickness which appears to be thicker in XDR strains. Also this can explain the partial 
increase of MIC values in presence of MDR strain. 
In conclusion, was demonstrated that Cin+CAMP(n) can successfully inhibit the growth 
of both clinical isolates Mtb and MDR in vitro. The characteristic proprieties of CAMPs 
may also be effectively used to separate the aggregated Mtb by interacting with surface 
of mycobacteria. Cin+CAMP1 and Cin+CAMP3 hold, for now, a promising usage as drug 
adjuvant due to its effect on mycobacteria growth. 
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5. Conclusions and Future perspectives  
 
At the end of this dissertation, we concluded that all proposed goals were accomplished. 
Both CAMP(n)s and Cin+CAMP(n)s were successfully synthesized by manual SPPS 
with high purification level. 
The MIC value and inhibition of growth against Mtb and MDR-TB clinical isolate was 
proved enhance in modified CAMPs (Cin+CAMPs) when compared with CAMPs. The 
exception was Cin+CAMP5 which demonstrated the same MIC of CAMP5 against Mtb 
and for MDR-TB CAMP5 was observed with enhance activity over Cin+CAMP5. 
In general, the coupling of cinnamic acid was proved to enhance the Cin+CAMP(n) 
activities. Unfortunately, the incorporation of cinnamic acid derivate into the CAMP(n) 
was also associated with loss of microbial selectivity demonstrating high levels of 
cytotoxicity towards THP-1 cells. Even though, observation features in cells culture and 
MIC50 values demonstrated an effective inhibition potential of Cin+CAMP(n) with the 
possible use adjuvant drug in the future. 
Overall, this investigation project demonstrated the prospective value of Cin+CAMP(n) 
as new therapeutically approach against Mtb and MDR-TB. 
In the future of this project, the next steps will require further optimization of 
Cin+CAMP(n) with the possible association with nanoparticles or Polyethylene glycol 
(PEG) delivery systems in order to lower the cytotoxicity observed. Moreover, possible 
evaluation of the synergy activity between Cin+CAMP(n) and conventional antibiotic. 
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6. Suplementary Information  
6.1. Work Plan 
	
The first phase of the project occured in the Department of Chemistry and Biochemistry 
of Faculty of Sciences, University of Porto, for development the cationic antimicrobial 
peptides (CAMPs):   
1. Five CAMPs with similar structure composed by 9 amino acids were synthesized 
using standard manual Fmoc SPPS. From the final volume of mass obtained, 
half was stored as CAMP without N-terminal modification (CAMP (n) and the 
remainder was modified with N-terminal modification with the coupling of one 
cinnamic derivative. 
2. Analysis and subsequent purification of the peptides was carried out by High 
Pressure Liquid Chromatography (HPLC) and Medium Pressure Liquid 
Chromatography (MPLC) 
3. The product characterization was confirmed by Liquid chromatography-mass 
spectrometry (LC-MS/MS). 
4. Final product obtained by lyophilization to remove the solvents present in the 
solution. 
 
After peptide synthesis, the Instituto Nacional de Saúde Dr. Ricardo Jorge (INSA) in 
Porto was fundamental for the determination of the minimum inhibitory concentration 
(MIC) of the ten CAMPs against Mtb. The tasks were: 
1. Antimicrobial activity for the ten CAMPs against MTB was determined through 
broth microdilution assay on a 96-well plate against Mtb H37Rv (standard strain 
and for quality control) and resistant clinical isolate MDR-Tb (resistance to INH, 
RIF and STR). 
2. CAMPs were diluted in modify Middlebrook Broth 7H9 (BD BACTEC™ MGIT™) 
supplemented with 10% Middlebrook oleic albumin, dextrose and catalase 
(OADC) growth supplement (BD BACTEC™ MGIT™ OADC). Serial dilutions of 
peptide (from 128 μg / ml to 0.25 μg / ml) were prepared in a volume of 180 μl of 
medium and 20 μl of bacterial suspension (Mc Farland nº1) added to the 96-well 
plates making a final volume of 200 μl. Plates were sealed and incubated at 37 ° 
for 7 days. For the negative control 180 μl of medium plus 20 μL of suspension 
added without peptides, for the positive control was used isoniazid and 
streptomycin (INH and STR) as reference drugs.  
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3. After 7 days at 37º C, the growth of Mtb were screened by visually comparing the 
growth and the morphology of the mycobacterial colonies with the control 
samples by light microscopy and through REMA method.  
 
In University of Minho was performed the cytotoxicity assay of the 5 Cin+CAMP(n) in 
order to determine the IC50 of the peptides against THP-1 human monocyte cell line: 
1. IC50 determined by the MTS assay previously describe in the article (Ramón-
García et al. 2013). 
	
Finally, all data were statistically analysed using program Prism (GraphPad Software). 
One way or two-way ANOVA. All experiments were performed at least twice. 
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6.2.  Peptides purification analysis. 
 
HPLC analysis of all peptide purified (Figure 39 – 48). 
	
Camp1		
	
	
Figure	39	-	Chromatogram	of	the	CAMP1	purified	peptide,	acquired	with	a	HPLC	system,	with	a	C18	column,	using	
ACN	in	water	with 0.05% TFA as eluent, in gradient mode (0 – 100%), for 30 minutes, at a flow of 1 mL/min and detection 
at λ = 220 nm.	
	
Cin+CAMP1		
	
	
Figure	40	-	Chromatogram	of	the	Cin+CAMP1	purified	peptide,	acquired	with	a	HPLC	system,	with	a	C18	column,	
using	ACN	in	water	with	0.05%	TFA	as	eluent,	in	gradient	mode	(0	–	100%),	for	30	minutes,	at	a	flow	of	1	mL/min	
and	detection	at	λ	=	220	
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CAMP2		
	
	
Figure	41	-	Chromatogram	of	the	CAMP2	purified	peptide,	acquired	with	a	HPLC	system,	with	a	C18	column,	using	
ACN	in	water	with	0.05%	TFA	as	eluent,	in	gradient	mode	(0	–	100%),	for	30	minutes,	at	a	flow	of	1	mL/min	and	
detection	at	λ	=	220.	
	
	
Cin+	Camp	2	
	
	
Figure	42	-	Chromatogram	of	the	Cin+CAMP2	purified	peptide,	acquired	with	a	HPLC	system,	with	a	C18	column,	
using	ACN	in	water	with	0.05%	TFA	as	eluent,	in	gradient	mode	(0	–	100%),	for	30	minutes,	at	a	flow	of	1	mL/min	
and	detection	at	λ	=	220	
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CAMP3	
	
	
Figure	43	-	Chromatogram	of	the	CAMP3	purified	peptide,	acquired	with	a	HPLC	system,	with	a	C18	column,	using	
ACN	in	water	with	0.05%	TFA	as	eluent,	in	gradient	mode	(0	–	100%),	for	30	minutes,	at	a	flow	of	1	mL/min	and	
detection	at	λ	=	220.	
	
	
	
Cin+CAMP3	
	
Figure	44	-	Chromatogram	of	the	Cin+CAMP3	purified	peptide,	acquired	with	a	HPLC	system,	with	a	C18	column,	
using	ACN	in	water	with	0.05%	TFA	as	eluent,	in	gradient	mode	(0	–	100%),	for	30	minutes,	at	a	flow	of	1	mL/min	
and	detection	at	λ	=	220	
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CAMP5	
	
	
Figure	45	-	Chromatogram	of	the	CAMP5	purified	peptide,	acquired	with	a	HPLC	system,	with	a	C18	column,	using	
ACN	in	water	with	0.05%	TFA	as	eluent,	in	gradient	mode	(0	–	100%),	for	30	minutes,	at	a	flow	of	1	mL/min	and	
detection	at	λ	=	220	
	
	
Cin-CAMP5	
	
	
Figure	46	-	Chromatogram	of	the	Cin+CAMP5	purified	peptide,	acquired	with	a	HPLC	system,	with	a	C18	column,	
using	ACN	in	water	with	0.05%	TFA	as	eluent,	in	gradient	mode	(0	–	100%),	for	30	minutes,	at	a	flow	of	1	mL/min	
and	detection	at	λ	=	220.		
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Camp	7	
	
Figure	47	-	Chromatogram	of	the	CAMP7	purified	peptide,	acquired	with	a	HPLC	system,	with	a	C18	column,	using	
ACN	in	water	with	0.05%	TFA	as	eluent,	in	gradient	mode	(0	–	100%),	for	30	minutes,	at	a	flow	of	1	mL/min	and	
detection	at	λ	=	220	
	
	
Cin+camp7	
	
	
Figure	48	-	Chromatogram	of	the	Cin+CAMP7	purified	peptide,	acquired	with	a	HPLC	system,	with	a	C18	column,	
using	ACN	in	water	with	0.05%	TFA	as	eluent,	in	gradient	mode	(0	–	100%),	for	30	minutes,	at	a	flow	of	1	mL/min	
and	detection	at	λ	=	220	
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